Breast Cancer Now responds to research into new breast cancer monitor that can be worn in a bra
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
18 Mar 2024
Breast Cancer Now responds to news of Olivia Munn's breast cancer diagnosis
Sally Kum, associate director of nursing, health information and healthcare professional engagement at Breast Cancer Now, said:
13 Mar 2024
Breast Cancer Now respond to Talazoparib (Talzenna) being approved for use on the NHS in Scotland
Responding to the decision by the Scottish Medicines Consortium (SMC) to recommend talazoparib (Talzenna) for use on the NHS in Scotland, Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
11 Mar 2024
Breast Cancer Now responds to latest Ombudsman report revealing over-stretched doctors could put cancer patients at risk
Baroness Delyth Morgan, chief executive at Breast Cancer Now, warns:
09 Mar 2024
Breast Cancer Now respond to today's Ministerial statement, regarding high risk screening error
Responding, Baroness Delyth Morgan, chief executive at Breast Cancer Now said:
05 Mar 2024
We respond to latest waiting times data in England - December 2023
Baroness Delyth Morgan, chief executive at Breast Cancer Now said:
08 Feb 2024
We respond to a new study from Cancer Research UK warning that progress in UK cancer survival is now slower than it has been for 50 years
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
02 Feb 2024
We respond to the launch of the new national NHS Jewish BRCA Testing Programme
Baroness Delyth Morgan, chief executive of Breast Cancer Now, said:
01 Feb 2024
Talazoparib (Talzenna) approved for use on the NHS in England
Responding to the National Institute of Health and Care Excellence (NICE) decision, Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
19 Jan 2024
Scottish Medicines Consortium (SMC) approves trastuzumab deruxtecan (Enhertu) for use on NHS in Scotland
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
11 Dec 2023
We respond to a policy review by leading cancer experts, published in The Lancet Oncology, on improving cancer care in the UK
Responding to a Policy Review by leading cancer experts, published in The Lancet Oncology, on improving cancer care in the UK, Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
15 Nov 2023
We respond to NHSE announcement of the license for anastrozole being extended to cover its use as a risk-reducing treatment for breast cancer
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
07 Nov 2023